Tuesday, February 26, 2019

MarketAxess Holdings Inc. (MKTX) Shares Bought by Comerica Bank

Comerica Bank grew its stake in shares of MarketAxess Holdings Inc. (NASDAQ:MKTX) by 1.4% in the fourth quarter, Holdings Channel reports. The fund owned 25,397 shares of the financial services provider’s stock after buying an additional 359 shares during the quarter. Comerica Bank’s holdings in MarketAxess were worth $5,422,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of MKTX. We Are One Seven LLC purchased a new stake in shares of MarketAxess during the 4th quarter worth about $26,000. Enlightenment Research LLC purchased a new stake in shares of MarketAxess during the 4th quarter worth about $42,000. Meeder Asset Management Inc. purchased a new stake in shares of MarketAxess during the 4th quarter worth about $81,000. Vectors Research Management LLC purchased a new stake in shares of MarketAxess during the 3rd quarter worth about $100,000. Finally, First Hawaiian Bank purchased a new stake in shares of MarketAxess during the 3rd quarter worth about $113,000. 99.17% of the stock is owned by institutional investors.

Get MarketAxess alerts:

MKTX has been the subject of a number of research reports. BidaskClub upgraded MarketAxess from a “hold” rating to a “buy” rating in a report on Tuesday, February 12th. Zacks Investment Research cut MarketAxess from a “hold” rating to a “sell” rating in a report on Thursday, January 17th. Buckingham Research started coverage on MarketAxess in a report on Thursday, January 10th. They issued a “neutral” rating for the company. Finally, Goldman Sachs Group started coverage on MarketAxess in a report on Monday, November 5th. They issued a “sell” rating for the company. Two analysts have rated the stock with a sell rating, six have issued a hold rating and two have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $215.50.

NASDAQ MKTX opened at $238.97 on Friday. The company has a market capitalization of $8.78 billion, a price-to-earnings ratio of 52.29, a P/E/G ratio of 9.03 and a beta of 0.11. MarketAxess Holdings Inc. has a fifty-two week low of $172.09 and a fifty-two week high of $239.51.

MarketAxess (NASDAQ:MKTX) last released its quarterly earnings results on Wednesday, January 30th. The financial services provider reported $1.21 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.15 by $0.06. The firm had revenue of $112.44 million during the quarter, compared to analysts’ expectations of $112.37 million. MarketAxess had a return on equity of 30.31% and a net margin of 39.69%. MarketAxess’s quarterly revenue was up 14.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.88 EPS. As a group, equities analysts forecast that MarketAxess Holdings Inc. will post 5.18 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, February 27th. Stockholders of record on Wednesday, February 13th will be paid a dividend of $0.51 per share. This is a boost from MarketAxess’s previous quarterly dividend of $0.42. This represents a $2.04 annualized dividend and a dividend yield of 0.85%. The ex-dividend date of this dividend is Tuesday, February 12th. MarketAxess’s dividend payout ratio is 44.64%.

In other news, Director John Steinhardt sold 3,187 shares of the stock in a transaction that occurred on Tuesday, February 5th. The stock was sold at an average price of $215.62, for a total transaction of $687,180.94. Following the completion of the transaction, the director now directly owns 24,899 shares in the company, valued at approximately $5,368,722.38. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Antonio L. Delise sold 8,000 shares of the stock in a transaction that occurred on Tuesday, February 19th. The shares were sold at an average price of $231.99, for a total value of $1,855,920.00. Following the transaction, the chief financial officer now owns 36,901 shares of the company’s stock, valued at $8,560,662.99. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 31,187 shares of company stock valued at $6,961,901. Company insiders own 3.52% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “MarketAxess Holdings Inc. (MKTX) Shares Bought by Comerica Bank” was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this article on another website, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The legal version of this article can be accessed at https://www.tickerreport.com/banking-finance/4173470/marketaxess-holdings-inc-mktx-shares-bought-by-comerica-bank.html.

MarketAxess Profile

MarketAxess Holdings Inc, together with its subsidiaries, operates an electronic trading platform that enables fixed-income market participants to trade corporate bonds and other types of fixed-income instruments worldwide. It offers institutional investor and broker-dealer the access to global liquidity in U.S.

Featured Article: Short Selling Stocks, A Beginner's Guide

Want to see what other hedge funds are holding MKTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MarketAxess Holdings Inc. (NASDAQ:MKTX).

Institutional Ownership by Quarter for MarketAxess (NASDAQ:MKTX)

Thursday, February 21, 2019

Societe Generale Increases Intercontinental Hotels Group (IHG) Price Target to GBX 4,800

Intercontinental Hotels Group (LON:IHG) had its price target increased by Societe Generale from GBX 4,500 ($58.80) to GBX 4,800 ($62.72) in a research note issued to investors on Wednesday. They currently have a hold rating on the stock.

Several other equities research analysts also recently commented on the stock. UBS Group upgraded shares of Intercontinental Hotels Group to a neutral rating and boosted their target price for the company from GBX 4,275 ($55.86) to GBX 4,500 ($58.80) in a research note on Wednesday. Bryan, Garnier & Co restated a sell rating on shares of Intercontinental Hotels Group in a research note on Tuesday. Barclays restated an equal weight rating on shares of Intercontinental Hotels Group in a research note on Thursday, February 7th. Morgan Stanley downgraded shares of Intercontinental Hotels Group from an equal rating to a weight rating in a research note on Monday, January 7th. Finally, Royal Bank of Canada began coverage on shares of Intercontinental Hotels Group in a research note on Tuesday, December 4th. They issued a sector performer rating and a GBX 4,500 ($58.80) target price on the stock. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and one has given a buy rating to the company’s stock. The company has a consensus rating of Hold and an average target price of GBX 4,740 ($61.94).

Get Intercontinental Hotels Group alerts:

Shares of LON:IHG opened at GBX 4,515.50 ($59.00) on Wednesday. Intercontinental Hotels Group has a 52 week low of GBX 3,656 ($47.77) and a 52 week high of GBX 4,944 ($64.60).

The firm also recently declared a dividend, which will be paid on Tuesday, May 14th. Investors of record on Thursday, March 28th will be issued a $0.78 dividend. The ex-dividend date of this dividend is Thursday, March 28th. This represents a dividend yield of 1.31%.

About Intercontinental Hotels Group

InterContinental Hotels Group PLC owns, manages, franchises, and leases hotels in the Americas, Europe, Asia, the Middle East, Africa, and Greater China. The company operates hotels, resorts, and restaurants under the InterContinental, Kimpton, Hotel Indigo, EVEN, HUALUXE, Crowne Plaza, Holiday Inn, Holiday Inn Express, Holiday Inn Club Vacations, Holiday Inn Resort, avid, Staybridge Suites, Candlewood Suites, and InterContinental Hotels & Resorts brands.

Recommended Story: How to trade on quiet period expirations

Analyst Recommendations for Intercontinental Hotels Group (LON:IHG)

Wednesday, February 20, 2019

Zacks: Analysts Anticipate Simmons First National Co. (SFNC) to Post $0.57 Earnings Per Share

Wall Street brokerages predict that Simmons First National Co. (NASDAQ:SFNC) will post earnings of $0.57 per share for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Simmons First National’s earnings. Simmons First National also reported earnings of $0.57 per share in the same quarter last year. The firm is expected to issue its next earnings results on Monday, April 22nd.

According to Zacks, analysts expect that Simmons First National will report full year earnings of $2.46 per share for the current fiscal year, with EPS estimates ranging from $2.40 to $2.53. For the next fiscal year, analysts expect that the firm will post earnings of $2.68 per share, with EPS estimates ranging from $2.54 to $2.88. Zacks’ EPS averages are a mean average based on a survey of research firms that cover Simmons First National.

Get Simmons First National alerts:

Simmons First National (NASDAQ:SFNC) last issued its earnings results on Tuesday, January 22nd. The bank reported $0.61 EPS for the quarter, meeting analysts’ consensus estimates of $0.61. Simmons First National had a return on equity of 10.14% and a net margin of 26.16%. The firm had revenue of $172.37 million for the quarter, compared to the consensus estimate of $177.84 million.

SFNC has been the topic of a number of recent research reports. Zacks Investment Research upgraded Simmons First National from a “hold” rating to a “buy” rating and set a $28.00 target price on the stock in a research note on Friday, October 26th. BidaskClub upgraded Simmons First National from a “sell” rating to a “hold” rating in a research note on Tuesday, October 30th. Stephens set a $32.00 target price on Simmons First National and gave the company a “buy” rating in a research note on Friday, November 16th. Finally, ValuEngine upgraded Simmons First National from a “strong sell” rating to a “sell” rating in a research note on Tuesday, November 20th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $31.60.

Shares of NASDAQ SFNC opened at $26.98 on Friday. The company has a current ratio of 1.00, a quick ratio of 1.00 and a debt-to-equity ratio of 0.76. Simmons First National has a one year low of $22.64 and a one year high of $33.45. The stock has a market capitalization of $2.46 billion, a price-to-earnings ratio of 11.38 and a beta of 1.06.

The business also recently declared a quarterly dividend, which will be paid on Friday, April 5th. Stockholders of record on Friday, March 15th will be paid a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a dividend yield of 2.37%. The ex-dividend date is Thursday, March 14th. This is an increase from Simmons First National’s previous quarterly dividend of $0.15. Simmons First National’s dividend payout ratio is 25.32%.

In related news, CEO George Makris, Jr. purchased 10,000 shares of the firm’s stock in a transaction dated Wednesday, January 30th. The stock was bought at an average price of $24.85 per share, for a total transaction of $248,500.00. Following the purchase, the chief executive officer now owns 220,766 shares in the company, valued at approximately $5,486,035.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 2.76% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Pearl River Capital LLC bought a new stake in shares of Simmons First National during the 4th quarter worth about $27,000. PNC Financial Services Group Inc. boosted its stake in shares of Simmons First National by 61.2% during the 4th quarter. PNC Financial Services Group Inc. now owns 4,098 shares of the bank’s stock worth $99,000 after acquiring an additional 1,556 shares in the last quarter. Quantamental Technologies LLC bought a new stake in shares of Simmons First National during the 4th quarter worth about $102,000. Paloma Partners Management Co bought a new stake in shares of Simmons First National during the 3rd quarter worth about $206,000. Finally, Jane Street Group LLC bought a new stake in shares of Simmons First National during the 2nd quarter worth about $256,000. Institutional investors own 52.62% of the company’s stock.

About Simmons First National

Simmons First National Corporation operates as the holding company for Simmons Bank that provides financial products and services to individuals and businesses. It offers checking, savings, and time deposits; loan products, including consumer, real estate, commercial, agricultural, equipment, and SBA lending; personal and corporate trust services; credit cards; investment management products; insurance products; and securities and investment services.

Further Reading: Cost of equity and a company's balance sheet

Get a free copy of the Zacks research report on Simmons First National (SFNC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Simmons First National (NASDAQ:SFNC)

Tuesday, February 19, 2019

Top 10 Heal Care Stocks To Buy Right Now

tags:HNT,SQ,DIA,SMBC,ARNA,DVN,EXTR,EVM,TNH,FNV,

ValuEngine downgraded shares of Vedanta (NYSE:VEDL) from a hold rating to a sell rating in a research report released on Wednesday.

NYSE:VEDL opened at $13.41 on Wednesday. The company has a debt-to-equity ratio of 0.34, a current ratio of 0.82 and a quick ratio of 0.64. Vedanta has a fifty-two week low of $13.01 and a fifty-two week high of $21.99. The stock has a market cap of $9.78 billion, a price-to-earnings ratio of 8.05 and a beta of 1.87.

Get Vedanta alerts:

Vedanta (NYSE:VEDL) last issued its quarterly earnings data on Thursday, May 3rd. The basic materials company reported $0.66 earnings per share (EPS) for the quarter. Vedanta had a return on equity of 24.61% and a net margin of 10.98%. The business had revenue of $4.29 billion for the quarter.

Top 10 Heal Care Stocks To Buy Right Now: Health Net Inc.(HNT)

Advisors' Opinion:
  • [By Ethan Ryder]

    Huntsworth (LON:HNT)‘s stock had its “add” rating reiterated by equities researchers at Peel Hunt in a research report issued to clients and investors on Monday.

  • [By Stephan Byrd]

    Huntsworth plc (LON:HNT) insider Paul Taaffe sold 1,243,445 shares of the firm’s stock in a transaction that occurred on Tuesday, October 9th. The stock was sold at an average price of GBX 110 ($1.44), for a total transaction of £1,367,789.50 ($1,787,259.24).

Top 10 Heal Care Stocks To Buy Right Now: Square, Inc.(SQ)

Advisors' Opinion:
  • [By Matthew Frankel]

    Fintech company Square (NYSE:SQ) has performed incredibly well for its investors. The stock is up by about 450% over the past three years and has risen by 106% in 2018 alone.

  • [By Shane Hupp]

    Bank of Montreal Can increased its position in shares of Square, Inc. (NYSE:SQ) by 15.4% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 207,054 shares of the technology company’s stock after buying an additional 27,603 shares during the quarter. Bank of Montreal Can’s holdings in Square were worth $11,612,000 as of its most recent SEC filing.

  • [By ]

    Schulman said that while he is a big believer in blockchain technology, PayPal and its mobile payments platform Venmo does not offer cryptocurrency exchange to protect its users, unlike competitors like Square's (SQ) Cash app.

Top 10 Heal Care Stocks To Buy Right Now: SPDR Dow Jones Industrial Average ETF (DIA)

Advisors' Opinion:
  • [By Shane Hupp]

    Traders bought shares of SPDR Dow Jones Industrial Average ETF Trust (NYSEARCA:DIA) on weakness during trading hours on Thursday. $242.64 million flowed into the stock on the tick-up and $212.95 million flowed out of the stock on the tick-down, for a money net flow of $29.69 million into the stock. Of all companies tracked, SPDR Dow Jones Industrial Average ETF Trust had the 29th highest net in-flow for the day. SPDR Dow Jones Industrial Average ETF Trust traded down ($0.64) for the day and closed at $255.16

  • [By Shane Hupp]

    Dynamic Advisor Solutions LLC lessened its position in SPDR Dow Jones Industrial Average ETF Trust (NYSEARCA:DIA) by 90.5% in the first quarter, according to its most recent disclosure with the SEC. The firm owned 1,526 shares of the exchange traded fund’s stock after selling 14,566 shares during the period. Dynamic Advisor Solutions LLC’s holdings in SPDR Dow Jones Industrial Average ETF Trust were worth $368,000 as of its most recent filing with the SEC.

  • [By Todd Shriber, ETF Professor]

    Year-to-date, the SPDR Dow Jones Industrial Average ETF (NYSE: DIA), the largest exchange traded fund tracking the Dow, is up 0.6 percent, including dividends paid.

Top 10 Heal Care Stocks To Buy Right Now: Southern Missouri Bancorp, Inc.(SMBC)

Advisors' Opinion:
  • [By Stephan Byrd]

    Southern Missouri Bancorp (NASDAQ: SMBC) and Heritage Financial (NASDAQ:HFWA) are both small-cap finance companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, dividends and analyst recommendations.

  • [By Joseph Griffin]

    Southern Missouri Bancorp (NASDAQ: SMBC) and First Connecticut Bancorp (NASDAQ:FBNK) are both small-cap finance companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, risk and dividends.

  • [By Joseph Griffin]

    Keefe, Bruyette & Woods initiated coverage on shares of Southern Missouri Bancorp (NASDAQ:SMBC) in a research note issued to investors on Thursday. The brokerage issued a market perform rating on the savings and loans company’s stock.

Top 10 Heal Care Stocks To Buy Right Now: Arena Pharmaceuticals, Inc.(ARNA)

Advisors' Opinion:
  • [By Stephan Byrd]

    Shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) traded up 6.2% during mid-day trading on Friday . The stock traded as high as $46.02 and last traded at $46.02. 753,200 shares were traded during mid-day trading, a decline of 13% from the average session volume of 863,629 shares. The stock had previously closed at $43.32.

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on Arena Pharmaceuticals (ARNA)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By ]

    In the Lightning Round, Cramer was bullish on Walgreens Boots Alliance (WBA) , Arena Pharmaceuticals (ARNA) , Dominion Energy (D) , Idexx Laboratories (IDXX) , GlaxoSmithKline (GSK) , Baidu.com (BIDU) , Baozun (BZUN) and Alibaba (BABA) .

  • [By Max Byerly]

    Northern Trust Corp grew its stake in shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) by 16.9% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 543,774 shares of the biopharmaceutical company’s stock after buying an additional 78,445 shares during the period. Northern Trust Corp owned 1.10% of Arena Pharmaceuticals worth $21,479,000 at the end of the most recent reporting period.

Top 10 Heal Care Stocks To Buy Right Now: Devon Energy Corporation(DVN)

Advisors' Opinion:
  • [By Matthew DiLallo]

    Devon Energy (NYSE:DVN) was one of those. While that company's CEO did note on Devon's quarterly conference call that capital expenditures would trend toward the high end of its guidance range, that's because Devon was "completing our plan 2018 program quicker than anticipated." As a result, the company would "most likely accelerate some 2019 program into 2018," even as it stays within its initial budget guidelines. Doing so will enable Devon to grow faster while still generating excess cash at current oil prices, which it's returning to shareholders through a $1 billion stock buyback and 33% dividend increase.

  • [By Tyler Crowe, Matthew DiLallo, and Reuben Gregg Brewer]

    So we asked three of our investing contributors to each highlight a company they think has a compelling investment case right now in the oil and gas industry. Here's why they selected Devon Energy (NYSE:DVN), Range Resources (NYSE:RRC), and ExxonMobil (NYSE:XOM).

  • [By ]

    In the Lightning Round, Cramer was bullish on PayPal (PYPL) , Wyndham Worldwide (WYN) , Churchill Downs (CHDN) , Devon Energy (DVN) , Discovery Communications (DISCA) and Cypress Semiconductor (CY) .

  • [By Joseph Griffin]

    Alps Advisors Inc. purchased a new position in Devon Energy Corp (NYSE:DVN) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 14,625 shares of the energy company’s stock, valued at approximately $605,000.

  • [By Stephan Byrd]

    These are some of the news headlines that may have impacted Accern Sentiment’s rankings:

    Get Devon Energy alerts: Devon Energy (DVN) Presents At UBS Global Oil and Gas Conference – Slideshow (seekingalpha.com) Devon Energy (DVN) Receives Average Rating of “Buy” from Analysts (americanbankingnews.com) Top 5 Upstream Revenues: Higher Realized Prices Drive Growth (finance.yahoo.com) Comparing Stocks: COP, OXY, DVN, EOG, and APC (finance.yahoo.com) Free Research Report as Devon Energy's Quarterly Revenues Advanced 7.29% (finance.yahoo.com)

    NYSE:DVN traded down $1.11 during trading hours on Friday, hitting $40.58. The company had a trading volume of 6,948,699 shares, compared to its average volume of 7,939,727. The stock has a market cap of $21.24 billion, a P/E ratio of 64.41, a price-to-earnings-growth ratio of 4.37 and a beta of 2.16. Devon Energy has a 52 week low of $28.79 and a 52 week high of $45.16. The company has a quick ratio of 1.04, a current ratio of 1.04 and a debt-to-equity ratio of 0.70.

  • [By Matthew DiLallo]

    Those buyback-driven gains suggest that companies that follow this strategy could replicate this outperformance. While several oil companies are buying back their shares this year, two oil stocks with the greatest potential for a big-time buyback-fueled rally in the coming months are Devon Energy (NYSE:DVN) and QEP Resources (NYSE:QEP).

Top 10 Heal Care Stocks To Buy Right Now: Extreme Networks Inc.(EXTR)

Advisors' Opinion:
  • [By Joseph Griffin]

    Extreme Networks (NASDAQ:EXTR) posted its earnings results on Wednesday. The technology company reported $0.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.19 by $0.01, Bloomberg Earnings reports. Extreme Networks had a positive return on equity of 43.61% and a negative net margin of 3.28%. The company had revenue of $278.30 million for the quarter, compared to analyst estimates of $279.22 million. During the same quarter in the previous year, the firm earned $0.17 earnings per share. The firm’s quarterly revenue was up 55.6% compared to the same quarter last year. Extreme Networks updated its Q1 guidance to $0.00-0.07 EPS.

  • [By Lisa Levin]

    Extreme Networks, Inc. (NASDAQ: EXTR) shares dropped 22 percent to $9.15 after the company reported downbeat earnings for its third quarter and issued weak Q4 guidance.

  • [By Ethan Ryder]

    Extreme Networks (NASDAQ:EXTR) insider Edward Meyercord acquired 20,000 shares of the stock in a transaction dated Monday, May 14th. The shares were bought at an average cost of $8.42 per share, with a total value of $168,400.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Top 10 Heal Care Stocks To Buy Right Now: Eaton Vance California Municipal Bond Fund(EVM)

Advisors' Opinion:
  • [By Ethan Ryder]

    Eaton Vance California Municipal Bond Fd (NYSEAMERICAN:EVM) declared a monthly dividend on Monday, June 4th, Wall Street Journal reports. Shareholders of record on Friday, June 22nd will be paid a dividend of 0.0395 per share by the investment management company on Friday, June 29th. This represents a $0.47 annualized dividend and a yield of 4.58%. The ex-dividend date of this dividend is Thursday, June 21st.

Top 10 Heal Care Stocks To Buy Right Now: Terra Nitrogen Company L.P.(TNH)

Advisors' Opinion:
  • [By Logan Wallace]

    Media stories about Terra Nitrogen (NYSE:TNH) have been trending somewhat negative this week, Accern Sentiment reports. The research firm identifies positive and negative press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Terra Nitrogen earned a news impact score of -0.02 on Accern’s scale. Accern also gave news articles about the basic materials company an impact score of 46.8553415416776 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

  • [By Joseph Griffin]

    Evogene (NASDAQ: EVGN) and Terra Nitrogen (NYSE:TNH) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, earnings, dividends and institutional ownership.

Top 10 Heal Care Stocks To Buy Right Now: Franco-Nevada Corporation(FNV)

Advisors' Opinion:
  • [By Scott Levine]

    Here are three starkly different opportunities -- Aqua America (NYSE:WTR), Franco-Nevada Corp. (NYSE:FNV), and Ecolab (NYSE:ECL) -- that could help investors avoid tossing and turning all night.

  • [By Reuben Gregg Brewer]

    Although gold streaming is something of a niche in the precious metals market, the largest competitors have been in the business since the 1980s, while new entrants are showing up as well (including hedge funds, private equity, and pension funds). Most investors, however, should probably stick with the largest, easiest to trade, and longest-tenured companies for now. Here are the top five.

    Company Market Cap Dividend Yield Franco-Nevada (NYSE:FNV) $13 billion 1.3% Wheaton Precious Metals (NYSE:WPM) $9 billion 1.7% Royal Gold (NASDAQ:RGLD) $6 billion 1.2% Osisko Gold Royalties Ltd. $1.6 billion 1.6% Sandstorm Gold Ltd. $800 million N/A Franco-Nevada

    The largest streaming company by market cap is Franco-Nevada. As noted above, it has investments in nearly 300 mines, 50 of which are producing. However, it has taken diversification further than its peers by investing in around 80 oil and natural gas assets (57 producing), following the same basic business model. It's not as pure a play on metals, but if you are looking for diversification, that non-precious-metals exposure is an interesting addition to the mix. That said, gold provides roughly 70% of its revenue, with silver at 15%, and oil and gas at just 7% (the rest is, effectively, "other"), meaning that gold is still the big driver of performance here. The company has increased its dividend annually for 10 consecutive years.

  • [By Joseph Griffin]

    Franco Nevada Corp (NYSE:FNV) (TSE:FNV) saw some unusual options trading on Tuesday. Stock traders bought 8,054 put options on the stock. This is an increase of 3,010% compared to the typical daily volume of 259 put options.

Monday, February 18, 2019

Hot Penny Stocks For 2019

tags:RIG,PTI,JST,SORL,

The Affordable Care Act (better known as "Obamacare") has completely rearranged the healthcare chessboard and left many wanting, frustrated and confused, especially now that its future has become less clear. And I think it's safe to say that the real beneficiaries of the ACA have been the insurance companies. 

As Washington tries to remedy the problems, we are still stuck with the No. 1 problem: How can we deliver low-cost healthcare to middle income families that are being buried with high insurance premiums and a scant provider network that changes year to year? 

---Sponsored Link--- IRA/401(k) ALERT: Secret IRS Loophole Will Save Your Life
Every day the US creeps further into debt and its taking your IRA/401K along with it. At the time of this writing the national debt was $20.5 trillion. Yes, you read that right. There is a simple and legal IRS loophole that can protect your IRA/401K without spending a penny. All you have to do is request the guide below to see how this IRS Loophole works. Download your FREE IRS Loophole Guide.

One solution that would make sense is for a national clinic and pharmacy to merge with an insurance company. This is exactly what the proposed CVS (NYSE: CVS)/Aetna (NYSE: AET) merger would provide. Not only would this merger be a good thing for a large segment of the American populous, it will certainly be a good thing for CVS.

Hot Penny Stocks For 2019: Transocean Inc.(RIG)

Advisors' Opinion:
  • [By Jim Crumly]

    As for individual stocks, Amazon.com (NASDAQ:AMZN) briefly broke through $1 trillion in valuation, and Transocean Ltd. (NYSE:RIG) announced plans to acquire Ocean Rig UDW (NASDAQ:ORIG).

  • [By Dan Caplinger]

    The stock market was mixed on Friday, with the Dow Jones Industrial Average climbing to record heights even as the Nasdaq Composite gave back some of its recent gains. Investors largely continued to play a waiting game, as little in the way of new economic data or readings on the geopolitical environment impeded generally bullish sentiment. Whenever stocks reach lofty heights, pauses are inevitable, but some were nevertheless able to climb higher. Transocean (NYSE:RIG), Novavax (NASDAQ:NVAX), and Steelcase (NYSE:SCS) were among the best performers on the day. Here's why they did so well.

  • [By Jason Hall and Tyler Crowe]

    In this week's episode of Industry Focus: Energy, host Nick Sciple, together with Jason Hall and Tyler Crowe, explain how offshore companies work, where the industry is today, and what investors should watch with these companies. Tune in to learn what sets Transocean (NYSE:RIG), Diamond Offshore (NYSE:DO), Seadrill (NYSE:SDRL), and Ensco (NYSE:ESV) apart from each other, what kind of risk/reward profile each company has to offer, some critical points and trends investors need to know before diving into offshore, and much more.

  • [By Ethan Ryder]

    D.B. Root & Company LLC acquired a new position in shares of Transocean (NYSE:RIG) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 30,040 shares of the offshore drilling services provider’s stock, valued at approximately $297,000.

  • [By Jason Hall, Tyler Crowe, and John Bromels]

    According to three Motley Fool contributors, there are still ample opportunities to profit in the oil and gas segment as some left-behind subsectors start to catch up to the higher price trend. Three in particular that are well-positioned going forward are Transocean LTD (NYSE:RIG), National-Oilwell Varco, Inc. (NYSE:NOV), and Devon Energy Corp (NYSE:DVN).  

  • [By Paul Ausick]

    Offshore drilling services company Transocean Ltd. (NYSE: RIG) announced Tuesday that it has agreed to acquire competitor Ocean Rig UDW Inc. (NASDAQ: ORIG) in a deal valued at $2.7 billion. Transocean will pay approximately $2.7 billion for Ocean Rig, including $12.75 and 1.6128 shares of newly issued Transocean stock for each share of Ocean Rig.

Hot Penny Stocks For 2019: Patni Computer Systems Limited(PTI)

Advisors' Opinion:
  • [By Chris Lange]

    Proteostasis Therapeutics Inc. (NASDAQ: PTI) saw its shares slide early on Thursday after the company reported that it had positive data from its early stage trial in cystic fibrosis (CF). These results come from the firm's ongoing Phase 1 dosing study of PTI-801 in CF patients on background Orkambi (lumacaftor/ivacaftor) therapy.

Hot Penny Stocks For 2019: Jinpan International Limited(JST)

Advisors' Opinion:
  • [By Joseph Griffin]

    Warburg Research set a €47.00 ($55.95) price target on JOST Werke (ETR:JST) in a report published on Friday. The firm currently has a buy rating on the stock.

  • [By Logan Wallace]

    A number of firms have modified their ratings and price targets on shares of JOST Werke (ETR: JST) recently:

    5/25/2018 – JOST Werke was given a new €46.00 ($53.49) price target on by analysts at Deutsche Bank AG. They now have a “buy” rating on the stock. 5/25/2018 – JOST Werke was given a new €46.00 ($53.49) price target on by analysts at Deutsche Bank AG. They now have a “buy” rating on the stock. 5/25/2018 – JOST Werke was given a new €47.00 ($54.65) price target on by analysts at Warburg Research. They now have a “buy” rating on the stock. 5/24/2018 – JOST Werke was given a new €45.00 ($52.33) price target on by analysts at JPMorgan Chase & Co.. They now have a “neutral” rating on the stock. 5/8/2018 – JOST Werke was given a new €46.00 ($53.49) price target on by analysts at Deutsche Bank AG. They now have a “buy” rating on the stock. 4/4/2018 – JOST Werke was given a new €47.00 ($54.65) price target on by analysts at Warburg Research. They now have a “buy” rating on the stock.

    Shares of JOST Werke traded down €0.15 ($0.17), hitting €38.10 ($44.30), during mid-day trading on Friday, according to MarketBeat. 8,510 shares of the company’s stock were exchanged, compared to its average volume of 35,469. JOST Werke AG has a 52 week low of €27.20 ($31.63) and a 52 week high of €47.50 ($55.23).

  • [By Joseph Griffin]

    JOST Werke AG (ETR:JST) has earned an average rating of “Buy” from the six research firms that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is €49.33 ($57.36).

  • [By Max Byerly]

    Hauck & Aufhaeuser set a €58.00 ($67.44) target price on JOST Werke (ETR:JST) in a report issued on Wednesday. The brokerage currently has a buy rating on the stock.

  • [By Joseph Griffin]

    Deutsche Bank set a €46.00 ($53.49) price target on JOST Werke (ETR:JST) in a research report sent to investors on Friday. The firm currently has a buy rating on the stock.

Hot Penny Stocks For 2019: SORL Auto Parts Inc.(SORL)

Advisors' Opinion:
  • [By Lisa Levin] Gainers Euro Tech Holdings Company Limited (NASDAQ: CLWT) shares rose 14.1 percent to $3.65 in the pre-market trading session after reporting 2017 year-end results. LightPath Technologies, Inc. (NASDAQ: LPTH) rose 13.3 percent to $2.43 in pre-market trading after reporting a third-quarter earnings beat. MYnd Analytics, Inc. (NASDAQ: MYND) rose 10.5 percent to $3.49 in pre-market trading. MYnd Analytics reported a Q2 net loss of $2.7 million on revenue of $459,900. SORL Auto Parts, Inc. (NASDAQ: SORL) shares rose 8.4 percent to $5.68 in pre-market trading after reporting upbeat Q1 results. Famous Dave's of America, Inc. (NASDAQ: DAVE) shares rose 7.7 percent to $8.40 in pre-market trading after the company reported upbeat earnings for its first quarter on Monday. Xenon Pharmaceuticals Inc. (NASDAQ: XENE) rose 7.5 percent to $6.45 in pre-market trading after the company presented XEN901 Phase 1 clinical update and XEN1101 TMS pharmacodynamic Phase 1 data. Mimecast Ltd (NASDAQ: MIME) rose 6.5 percent to $43.50 in pre-market trading following a first-quarter sales beat. Boxlight Corporation (NASDAQ: BOXL) rose 6 percent to $12.50 in pre-market trading after surging 77.44 percent on Monday. Intellia Therapeutics, Inc. (NASDAQ: NTLA) shares rose 6 percent to $26.05 in pre-market trading after climbing 3.58 percent on Monday. PPDAI Group Inc. (NASDAQ: PPDF) rose 4.7 percent to $7.20 in pre-market trading following Q1 results. Xunlei Limited (NASDAQ: XNET) rose 4.1 percent to $13.88 in pre-market trading after gaining 2.54 percent on Monday. Valeant Pharmaceuticals International, Inc. (NYSE: VRX) shares rose 4.5 percent to $21.73 in pre-market trading. Mizuho upgraded Valeant from Neutral to Buy. Bovie Medical Corporation (NYSE: BVX) rose 4.1 percent to $3.80 in pre-market trading after reporting a first-quarter sales beat. Myomo, Inc. (NYSE: MYO) rose 3.4 percent to $4.00 in pre-market trading after jumping 23.25 percent o
  • [By Stephan Byrd]

    Icahn Enterprises LP Common Stock (NASDAQ: SORL) and Sorl Auto Parts (NASDAQ:SORL) are both multi-sector conglomerates companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

  • [By Lisa Levin]

    Shares of SORL Auto Parts, Inc. (NASDAQ: SORL) got a boost, shooting up 13 percent to $5.90 after reporting upbeat Q1 results.

    Hollysys Automation Technologies Ltd. (NASDAQ: HOLI) shares were also up, gaining 24 percent to $27.3947 following Q3 results.

  • [By Lisa Levin] Gainers Red Violet, Inc. (NASDAQ: RDVT) rose 75.31 percent to close at $9.94 after reporting Q1 results. Euro Tech Holdings Company Limited (NASDAQ: CLWT) shares jumped 40.62 percent to close at $4.50 on Tuesday after reporting 2017 year-end results. MEI Pharma, Inc. (NASDAQ: MEIP) gained 34.39 percent to close at $3.40. MEDIGUS Ltd/S ADR (NASDAQ: MDGS) gained 32.74 percent to close at $1.50 in reaction to its Monday announcement of a distribution agreement. The medical device company said it reached an agreement to distribute its minimally invasive medical devices in Turkey, Azerbaijan and Georgia. Pfenex Inc. (NYSE: PFNX) surged 31.15 percent to close at $8.00 after the company announced the positive top-line PF708 study results in Osteoporosis patients that showed no imbalances in severity or incidence of adverse events. Arcadia Biosciences, Inc. (NASDAQ: RKDA) rose 21.07 percent to close at $11.09. Arcadia Biosciences reported that Albert D. Bolles, Ph.D. has joined its board of directors. Genprex, Inc. (NASDAQ: GNPX) rose 20.23 percent to close at $10.58. Turtle Beach Corporation (NASDAQ: HEAR) shares gained 17.62 percent to close at $17.82. Aptevo Therapeutics Inc. (NASDAQ: APVO) rose 17.1 percent to close at $5.82. Phoenix New Media Limited (NYSE: FENG) shares jumped 16.23 percent to close at $4.87 following Q1 earnings. Stein Mart, Inc. (NASDAQ: SMRT) rose 16.04 percent to close at $3.69. PPDAI Group Inc. (NASDAQ: PPDF) climbed 15.99 percent to close at $7.98 following Q1 results. Tyme Technologies, Inc. (NASDAQ: TYME) rose 15.93 percent to close at $3.42. LiqTech International, Inc. (NASDAQ: LIQT) gained 15.59 percent to close at $0.5532 following Q1 results. Sophiris Bio, Inc. (NASDAQ: SPHS) gained 13.92 percent to close at $3.52 on Tuesday following Q1 results. Euroseas Ltd. (NASDAQ: ESEA) jumped 13.4 percent to close at $2.37. Iteris, Inc. (NASDAQ: ITI) shares surged 13.05 percent to close

Sunday, February 17, 2019

Arista Networks Inc (ANET) Files 10-K for the Fiscal Year Ended on December 31, 2018

Arista Networks Inc (NYSE:ANET) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. Arista Networks Inc is a supplier of cloud networking solutions that use software innovations to address the needs of large-scale Internet companies, cloud service providers, and next-generation data centers for enterprise support. Arista Networks Inc has a market cap of $19.91 billion; its shares were traded at around $263.95 with a P/E ratio of 85.71 and P/S ratio of 10.31. Arista Networks Inc had annual average EBITDA growth of 49.20% over the past five years.

For the last quarter Arista Networks Inc reported a revenue of $563.3 million, compared with the revenue of $437.6 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $2.2 billion, an increase of 30.7% from last year. For the last five years Arista Networks Inc had an average revenue growth rate of 42.2% a year.

The reported diluted earnings per share was $4.06 for the year, a decline of 24.1% from the previous year. Over the last five years Arista Networks Inc had an EPS growth rate of 46% a year. The Arista Networks Inc enjoyed an operating margin of 31.53%, compared with the operating margin of 28.57% a year before. The 10-year historical median operating margin of Arista Networks Inc is 21.49%. The profitability rank of the company is 8 (out of 10).

At the end of the fiscal year, Arista Networks Inc has the cash and cash equivalents of $650.0 million, compared with $859.2 million in the previous year. The long term debt was $35.4 million, compared with $37.7 million in the previous year. The interest coverage to the debt is at a comfortable level of 251.1. Arista Networks Inc has a financial strength rank of 9 (out of 10).

At the current stock price of $263.95, Arista Networks Inc is traded at 28.2% premium to its historical median P/S valuation band of $205.90. The P/S ratio of the stock is 10.31, while the historical median P/S ratio is 8.04. The stock lost 14.29% during the past 12 months.

Directors and Officers Recent Trades:

CTO and SVP Software Eng. Kenneth Duda sold 11,000 shares of ANET stock on 02/11/2019 at the average price of $229.04. The price of the stock has increased by 15.24% since.SVP and General Counsel Marc Taxay sold 2,000 shares of ANET stock on 02/01/2019 at the average price of $218.11. The price of the stock has increased by 21.02% since.

For the complete 20-year historical financial data of ANET, click here.

Equity Commonwealth (EQC) Files 10-K for the Fiscal Year Ended on December 31, 2018

Equity Commonwealth (NYSE:EQC) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. Equity Commonwealth is an internally managed and self-advised real estate investment trust. The company is engaged in the ownership and operation of office and industrial buildings throughout the United States. Equity Commonwealth has a market cap of $3.96 billion; its shares were traded at around $32.63 with a P/E ratio of 17.83 and P/S ratio of 18.00.

For the last quarter Equity Commonwealth reported a revenue of $42.9 million, compared with the revenue of $71.62 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $197.0 million, a decrease of 42.1% from the previous year. For the last five years Equity Commonwealth had an average revenue decline of 26.3% a year.

The reported diluted earnings per share was $2.15 for the year, an increase of 1164.7% from previous year. The Equity Commonwealth had a decent operating margin of 11.99%, compared with the operating margin of 17.82% a year before. The 10-year historical median operating margin of Equity Commonwealth is 25.71%. The profitability rank of the company is 5 (out of 10).

At the end of the fiscal year, Equity Commonwealth has the cash and cash equivalents of $2.4 billion, compared with $2.4 billion in the previous year. The long term debt was $275.0 million, compared with $848.6 million in the previous year. The company's operating income of cannot cover its interest payment during the last fiscal year. Equity Commonwealth has a financial strength rank of 7 (out of 10).

At the current stock price of $32.63, Equity Commonwealth is traded at 634.9% premium to its historical median P/S valuation band of $4.44. The P/S ratio of the stock is 18.00, while the historical median P/S ratio is 2.45. The stock gained 23.05% during the past 12 months.

For the complete 20-year historical financial data of EQC, click here.

Saturday, February 16, 2019

This range for the S&P 500 'makes me very nervous,' technician says

The S&P 500 has almost completely recovered from the December slump.

The benchmark index has rebounded 17 percent from its lows late last year and sits just over 50 points from its Dec. 3 high.

Its next move higher is going to be harder to come by, saidTodd Gordon, founder of TradingAnalysis.com.

"This area right here makes me very nervous because there's actually four significant technical levels here," Gordon said Thursday on CNBC's "Trading Nation." "The 200-day moving average right here — we have tried it once, twice, three, coming back on a fourth time."

The S&P 500 broke above and below that long-term trend line throughout the fourth quarter, only resurfacing above it earlier this month. Its failed attempts to firmly go above that line has formed a quadruple top, Gordon said.

"This is going to be a deadly battleground," said Gordon. "I want to short it but I want to be very diligent and get a good price, stop out above 2,900, but again, don't think is going to be an easy trade. I think we sell off but it's going to be very volatile for a period while we decide what to do here."

Erin Gibbs, portfolio manager at S&P Global, said markets should head higher, but it will be difficult to harness the momentum of years past.

"We're right at a three-year average when it comes to valuations but we're in this environment of much lower growth, slightly higher interest rates and so we're cautiously optimistic," Gibbs said Thursday on "Trading Nation." "We're really not looking for much more than a 5 percent increase in the near term."

A 5 percent rise by the end of the year would put the S&P 500 at 2,883, above its December top. It would remain below its September record high.

"Right now we're at 16.5 times forward earnings which has been the major support over the past few years but again that was a completely different environment," Gibbs said. "If we can break above 16.5, we see some real positive sentiment going forward, some better growth than, yeah, we would be much more optimistic."

Gibbs anticipates 4.6 percent blended earnings growth for the S&P 500 this year, well below the 22 percent pace in 2018.

Disclaimer

Thursday, February 14, 2019

Texas Instruments Incorporated (TXN) Expected to Announce Earnings of $1.13 Per Share

Equities research analysts predict that Texas Instruments Incorporated (NASDAQ:TXN) will report earnings of $1.13 per share for the current fiscal quarter, according to Zacks Investment Research. Eight analysts have provided estimates for Texas Instruments’ earnings, with estimates ranging from $1.10 to $1.18. Texas Instruments reported earnings of $1.21 per share during the same quarter last year, which would indicate a negative year over year growth rate of 6.6%. The firm is scheduled to issue its next quarterly earnings results on Tuesday, April 23rd.

According to Zacks, analysts expect that Texas Instruments will report full year earnings of $5.21 per share for the current fiscal year, with EPS estimates ranging from $5.00 to $5.61. For the next financial year, analysts forecast that the company will report earnings of $5.76 per share, with EPS estimates ranging from $5.40 to $6.83. Zacks’ earnings per share calculations are an average based on a survey of research analysts that cover Texas Instruments.

Get Texas Instruments alerts:

Texas Instruments (NASDAQ:TXN) last issued its quarterly earnings results on Wednesday, January 23rd. The semiconductor company reported $1.27 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.24 by $0.03. The firm had revenue of $3.72 billion during the quarter, compared to the consensus estimate of $3.75 billion. Texas Instruments had a return on equity of 53.05% and a net margin of 35.35%. The company’s revenue for the quarter was down .9% on a year-over-year basis. During the same quarter last year, the company posted $1.09 EPS.

A number of analysts have recently issued reports on the company. BidaskClub upgraded Texas Instruments from a “sell” rating to a “hold” rating in a research report on Wednesday. Zacks Investment Research cut Texas Instruments from a “hold” rating to a “sell” rating in a report on Monday, January 28th. Robert W. Baird reissued a “hold” rating and set a $97.00 price objective on shares of Texas Instruments in a report on Tuesday, February 5th. BMO Capital Markets reissued a “buy” rating and set a $120.00 price objective on shares of Texas Instruments in a report on Thursday, January 24th. Finally, Goldman Sachs Group raised Texas Instruments from a “sell” rating to a “neutral” rating in a report on Thursday, October 18th. Two research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and eleven have assigned a buy rating to the stock. Texas Instruments currently has a consensus rating of “Hold” and an average price target of $108.74.

In other Texas Instruments news, Director Pamela H. Patsley sold 7,000 shares of Texas Instruments stock in a transaction that occurred on Wednesday, February 6th. The stock was sold at an average price of $106.20, for a total value of $743,400.00. Following the transaction, the director now directly owns 37,160 shares of the company’s stock, valued at approximately $3,946,392. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Ahmad Bahai sold 26,963 shares of Texas Instruments stock in a transaction that occurred on Friday, January 25th. The stock was sold at an average price of $103.75, for a total value of $2,797,411.25. Following the completion of the transaction, the insider now directly owns 58,928 shares in the company, valued at $6,113,780. The disclosure for this sale can be found here. Insiders sold a total of 178,044 shares of company stock worth $18,178,452 over the last ninety days. Insiders own 0.84% of the company’s stock.

Institutional investors have recently made changes to their positions in the business. Highwater Wealth Management LLC purchased a new position in shares of Texas Instruments during the fourth quarter valued at approximately $34,000. Intercontinental Wealth Advisors LLC purchased a new position in shares of Texas Instruments during the fourth quarter valued at approximately $40,000. Essex Savings Bank purchased a new position in shares of Texas Instruments during the fourth quarter valued at approximately $42,000. Baldwin Brothers Inc. MA increased its stake in shares of Texas Instruments by 42.5% during the fourth quarter. Baldwin Brothers Inc. MA now owns 513 shares of the semiconductor company’s stock valued at $48,000 after buying an additional 153 shares during the period. Finally, Clarus Wealth Advisors increased its stake in shares of Texas Instruments by 142.9% during the fourth quarter. Clarus Wealth Advisors now owns 714 shares of the semiconductor company’s stock valued at $67,000 after buying an additional 420 shares during the period. 86.92% of the stock is currently owned by institutional investors and hedge funds.

Shares of TXN opened at $106.44 on Friday. The stock has a market cap of $100.42 billion, a PE ratio of 19.64, a price-to-earnings-growth ratio of 1.98 and a beta of 1.17. The company has a quick ratio of 2.38, a current ratio of 3.27 and a debt-to-equity ratio of 0.48. Texas Instruments has a 12-month low of $87.70 and a 12-month high of $118.48.

The business also recently declared a quarterly dividend, which was paid on Monday, February 11th. Shareholders of record on Thursday, January 31st were paid a $0.77 dividend. The ex-dividend date of this dividend was Wednesday, January 30th. This represents a $3.08 dividend on an annualized basis and a yield of 2.89%. Texas Instruments’s dividend payout ratio (DPR) is currently 56.83%.

About Texas Instruments

Texas Instruments Incorporated designs, manufactures, and sells semiconductors to electronics designers and manufacturers worldwide. It operates in two segments, Analog and Embedded Processing. The Analog segment offers power products to manage power requirements in various levels using battery management solutions, portable components, power supply controls, point-of-load products, switches and interfaces, integrated protection devices, high-voltage products, and mobile lighting and display products.

Further Reading: How Does the Quiet Period Work?

Get a free copy of the Zacks research report on Texas Instruments (TXN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Texas Instruments (NASDAQ:TXN)

Wednesday, February 13, 2019

Traders Buy Shares of Bristol-Myers Squibb (BMY) on Weakness

Investors bought shares of Bristol-Myers Squibb Co (NYSE:BMY) on weakness during trading hours on Monday. $155.60 million flowed into the stock on the tick-up and $108.92 million flowed out of the stock on the tick-down, for a money net flow of $46.68 million into the stock. Of all equities tracked, Bristol-Myers Squibb had the 23rd highest net in-flow for the day. Bristol-Myers Squibb traded down ($0.12) for the day and closed at $50.10

BMY has been the topic of a number of research analyst reports. Credit Suisse Group set a $61.00 price objective on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a report on Sunday, October 14th. ValuEngine lowered shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a report on Friday, October 19th. Citigroup lowered shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $62.00 to $57.00 in a report on Monday, October 22nd. William Blair reaffirmed an “outperform” rating on shares of Bristol-Myers Squibb in a report on Monday, October 22nd. Finally, Wolfe Research initiated coverage on shares of Bristol-Myers Squibb in a report on Tuesday, October 23rd. They issued an “outperform” rating and a $66.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating and seven have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $60.21.

Get Bristol-Myers Squibb alerts:

The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.40 and a current ratio of 1.53. The firm has a market cap of $81.97 billion, a P/E ratio of 12.59, a price-to-earnings-growth ratio of 1.60 and a beta of 0.83.

Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, January 24th. The biopharmaceutical company reported $0.94 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.85 by $0.09. Bristol-Myers Squibb had a net margin of 21.95% and a return on equity of 50.03%. The business had revenue of $5.97 billion for the quarter, compared to analyst estimates of $5.95 billion. During the same period in the prior year, the company posted $0.68 EPS. The company’s revenue for the quarter was up 9.6% on a year-over-year basis. On average, analysts predict that Bristol-Myers Squibb Co will post 4.16 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Friday, February 1st. Stockholders of record on Friday, January 4th were paid a dividend of $0.41 per share. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.40. This represents a $1.64 annualized dividend and a dividend yield of 3.27%. The ex-dividend date of this dividend was Thursday, January 3rd. Bristol-Myers Squibb’s dividend payout ratio is presently 41.21%.

Several hedge funds have recently bought and sold shares of BMY. SFE Investment Counsel raised its position in shares of Bristol-Myers Squibb by 8.6% during the 3rd quarter. SFE Investment Counsel now owns 16,375 shares of the biopharmaceutical company’s stock worth $1,017,000 after purchasing an additional 1,290 shares during the last quarter. Benedict Financial Advisors Inc. raised its position in shares of Bristol-Myers Squibb by 4.0% during the 3rd quarter. Benedict Financial Advisors Inc. now owns 25,248 shares of the biopharmaceutical company’s stock worth $1,567,000 after purchasing an additional 974 shares during the last quarter. Yorktown Management & Research Co Inc raised its position in shares of Bristol-Myers Squibb by 400.0% during the 3rd quarter. Yorktown Management & Research Co Inc now owns 20,000 shares of the biopharmaceutical company’s stock worth $1,242,000 after purchasing an additional 16,000 shares during the last quarter. Hollencrest Capital Management raised its position in shares of Bristol-Myers Squibb by 176.1% during the 4th quarter. Hollencrest Capital Management now owns 9,604 shares of the biopharmaceutical company’s stock worth $499,000 after purchasing an additional 6,126 shares during the last quarter. Finally, Highwater Wealth Management LLC acquired a new position in shares of Bristol-Myers Squibb during the 4th quarter worth about $170,000. 73.19% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This report was first published by Ticker Report and is the property of of Ticker Report. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this report can be viewed at https://www.tickerreport.com/banking-finance/4144371/traders-buy-shares-of-bristol-myers-squibb-bmy-on-weakness.html.

Bristol-Myers Squibb Company Profile (NYSE:BMY)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and human immunodeficiency virus (HIV) infection. Its products include Opdivo, a biological product for anti-cancer indications; Eliquis, an inhibitor targeted at stroke prevention in atrial fibrillation and prevention and treatment of venous thromboembolic disorders; Orencia, a biological product that targets adult patients with active rheumatoid arthritis and prostate-specific antigen; and Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Featured Story: What does EPS mean?

Tuesday, February 12, 2019

Shopify Earnings: SHOP Stock Slides Lower Despite Q4 Beat

Shopify earnings for the fourth quarter of 2018 are out and SHOP stock is down despite it beating estimates.

Shopify Earnings: SHOP Stock Slides Lower Despite Q4 BeatShopify Earnings: SHOP Stock Slides Lower Despite Q4 BeatSource: Shopify via Flickr

Shopify (NYSE:SHOP) reports that earnings per share for the fourth quarter of the year were 26 cents. This is an increase over its earnings per share of 15 cents from the same time last year. It also beat out Wall Street’s earnings per share estimate of 20 cents for the quarter, but that was unable to keep SHOP stock from falling today.

The Shopify earnings report for the fourth quarter of 2018 also includes a net loss of $1.51 million. This isn’t as bad as the company’s net loss of $2.99 million reported in the fourth quarter of 2017.

Operating loss reported by Shopify for the fourth quarter of the year was $9.46 million. The online shopping company reported an operating loss of $6.11 million during the same period of the year prior.

The most recent Shopify earnings release also has the company reporting revenue of $343.86 million. This is better than the company’s revenue of $222.81 million reported in the fourth quarter of the previous year. It also comes above analysts’ revenue estimate of $327.63 million for the period, but SHOP stock is still down on Tuesday.

The earnings report from Shopify also includes its outlook for the full year of 2019. This guidance has the company expecting revenue between $1.46 billion and $1.48 billion. Wall Street is looking for revenue of $1.48 billion for 2019.

SHOP stock was down 2% as of Tuesday morning, but is up 25% year-to-date.

As of this writing, William White did not hold a position in any of the aforementioned securities.

Compare Brokers

Monday, February 11, 2019

Jernigan Capital Inc (JCAP) Receives Consensus Recommendation of “Buy” from Brokerages

Shares of Jernigan Capital Inc (NYSE:JCAP) have received an average recommendation of “Buy” from the seven research firms that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have given a buy recommendation to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $24.00.

JCAP has been the subject of a number of recent analyst reports. Raymond James upped their price objective on shares of Jernigan Capital from $22.00 to $24.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 11th. KeyCorp set a $23.00 price objective on shares of Jernigan Capital and gave the stock a “buy” rating in a research report on Wednesday, November 28th. Zacks Investment Research raised shares of Jernigan Capital from a “sell” rating to a “hold” rating in a research report on Wednesday, November 28th. Finally, B. Riley set a $26.00 price objective on shares of Jernigan Capital and gave the stock a “buy” rating in a research report on Tuesday, October 30th.

Get Jernigan Capital alerts:

In other Jernigan Capital news, Director James D. Dondero sold 19,081 shares of the company’s stock in a transaction dated Friday, December 14th. The shares were sold at an average price of $21.17, for a total value of $403,944.77. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 2.40% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the company. Loeb Partners Corp bought a new position in shares of Jernigan Capital during the 4th quarter valued at approximately $40,000. Macquarie Group Ltd. bought a new position in shares of Jernigan Capital during the 2nd quarter valued at approximately $160,000. Nisa Investment Advisors LLC bought a new position in shares of Jernigan Capital during the 4th quarter valued at approximately $224,000. American International Group Inc. grew its position in shares of Jernigan Capital by 35.4% during the 3rd quarter. American International Group Inc. now owns 11,927 shares of the real estate investment trust’s stock valued at $230,000 after acquiring an additional 3,116 shares during the period. Finally, MetLife Investment Advisors LLC grew its position in shares of Jernigan Capital by 182.7% during the 3rd quarter. MetLife Investment Advisors LLC now owns 13,798 shares of the real estate investment trust’s stock valued at $266,000 after acquiring an additional 8,918 shares during the period. 68.16% of the stock is owned by hedge funds and other institutional investors.

Shares of JCAP traded down $0.05 on Tuesday, reaching $21.58. The company’s stock had a trading volume of 88,075 shares, compared to its average volume of 115,383. Jernigan Capital has a twelve month low of $16.62 and a twelve month high of $22.05. The firm has a market capitalization of $420.25 million, a PE ratio of 19.98 and a beta of 0.59.

Jernigan Capital Company Profile

Jernigan Capital, Inc is a New York Stock Exchange-listed real estate investment trust (NYSE: JCAP) that provides debt and equity capital to private developers, owners, and operators of self-storage facilities. Our mission is to be the preeminent capital partner for self-storage entrepreneurs nationwide by offering creative solutions through an experienced team demonstrating the highest levels of integrity, dedication, excellence and community, while maximizing shareholder value.

See Also: Short Selling Stocks, A Beginner's Guide

Sunday, February 10, 2019

Brokerages Expect Invesco Ltd. (IVZ) to Post $0.49 EPS

Wall Street brokerages expect that Invesco Ltd. (NYSE:IVZ) will report $0.49 earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Invesco’s earnings, with estimates ranging from $0.43 to $0.56. Invesco posted earnings of $0.67 per share in the same quarter last year, which would indicate a negative year over year growth rate of 26.9%. The business is scheduled to announce its next earnings results on Thursday, April 25th.

According to Zacks, analysts expect that Invesco will report full year earnings of $2.22 per share for the current year, with EPS estimates ranging from $1.95 to $2.60. For the next financial year, analysts expect that the firm will post earnings of $2.64 per share, with EPS estimates ranging from $2.20 to $3.00. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research firms that follow Invesco.

Get Invesco alerts:

Invesco (NYSE:IVZ) last announced its quarterly earnings data on Wednesday, January 30th. The asset manager reported $0.44 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.54 by ($0.10). Invesco had a net margin of 16.61% and a return on equity of 10.88%. The business had revenue of $919.20 million during the quarter, compared to analysts’ expectations of $913.37 million. During the same quarter in the previous year, the firm earned $0.73 earnings per share. Invesco’s revenue was down 8.5% on a year-over-year basis.

Several equities analysts have recently commented on IVZ shares. Zacks Investment Research downgraded Invesco from a “hold” rating to a “strong sell” rating in a research report on Tuesday, January 8th. Barclays lowered their price objective on Invesco from $25.00 to $23.00 and set an “overweight” rating on the stock in a research report on Monday, December 3rd. Deutsche Bank downgraded Invesco from a “buy” rating to a “hold” rating and lowered their price objective for the company from $25.00 to $18.00 in a research report on Thursday, January 10th. Wells Fargo & Co downgraded Invesco from an “outperform” rating to a “market perform” rating and lowered their price objective for the company from $27.00 to $22.00 in a research report on Tuesday, December 4th. Finally, Citigroup lowered their price objective on Invesco from $23.00 to $18.00 and set a “neutral” rating on the stock in a research report on Wednesday, December 19th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and two have given a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $25.18.

Shares of Invesco stock traded down $0.50 during trading hours on Friday, hitting $17.87. The company’s stock had a trading volume of 140,961 shares, compared to its average volume of 4,898,129. Invesco has a 12-month low of $15.38 and a 12-month high of $35.03. The company has a market capitalization of $7.46 billion, a price-to-earnings ratio of 7.35, a PEG ratio of 1.10 and a beta of 1.50. The company has a quick ratio of 1.55, a current ratio of 1.55 and a debt-to-equity ratio of 0.82.

The company also recently announced a quarterly dividend, which will be paid on Friday, March 1st. Investors of record on Thursday, February 14th will be given a $0.30 dividend. The ex-dividend date is Wednesday, February 13th. This represents a $1.20 dividend on an annualized basis and a dividend yield of 6.72%. Invesco’s dividend payout ratio is currently 49.38%.

Several large investors have recently bought and sold shares of IVZ. Rational Advisors LLC lifted its position in shares of Invesco by 411.3% in the fourth quarter. Rational Advisors LLC now owns 2,536 shares of the asset manager’s stock worth $42,000 after buying an additional 2,040 shares in the last quarter. Old North State Trust LLC lifted its position in shares of Invesco by 71.1% in the fourth quarter. Old North State Trust LLC now owns 3,746 shares of the asset manager’s stock worth $62,000 after buying an additional 1,557 shares in the last quarter. Oregon Public Employees Retirement Fund lifted its position in shares of Invesco by 3,044.9% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 1,419,067 shares of the asset manager’s stock worth $85,000 after buying an additional 1,373,944 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. lifted its position in shares of Invesco by 80.6% in the third quarter. Migdal Insurance & Financial Holdings Ltd. now owns 5,689 shares of the asset manager’s stock worth $130,000 after buying an additional 2,539 shares in the last quarter. Finally, First Interstate Bank lifted its position in shares of Invesco by 33.3% in the fourth quarter. First Interstate Bank now owns 10,000 shares of the asset manager’s stock worth $167,000 after buying an additional 2,500 shares in the last quarter. Institutional investors own 79.73% of the company’s stock.

About Invesco

Invesco Ltd. is a publicly owned investment manager. The firm provides its services to retail clients, institutional clients, high-net worth clients, public entities, corporations, unions, non-profit organizations, endowments, foundations, pension funds, financial institutions, and sovereign wealth funds.

Featured Article: Insider Trading

Get a free copy of the Zacks research report on Invesco (IVZ)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Invesco (NYSE:IVZ)

Saturday, February 9, 2019

Abbott Laboratories (ABT) Holdings Increased by Congress Asset Management Co. MA

Congress Asset Management Co. MA raised its holdings in shares of Abbott Laboratories (NYSE:ABT) by 563.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 700,720 shares of the healthcare product maker’s stock after acquiring an additional 595,043 shares during the period. Congress Asset Management Co. MA’s holdings in Abbott Laboratories were worth $50,683,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Csenge Advisory Group acquired a new position in shares of Abbott Laboratories in the 3rd quarter worth $31,000. Brand Asset Management Group Inc. grew its holdings in shares of Abbott Laboratories by 66.7% in the 4th quarter. Brand Asset Management Group Inc. now owns 500 shares of the healthcare product maker’s stock worth $36,000 after acquiring an additional 200 shares during the last quarter. Cornerstone Advisors Inc. grew its holdings in shares of Abbott Laboratories by 33.2% in the 4th quarter. Cornerstone Advisors Inc. now owns 1,199 shares of the healthcare product maker’s stock worth $87,000 after acquiring an additional 299 shares during the last quarter. NuWave Investment Management LLC grew its holdings in shares of Abbott Laboratories by 402.4% in the 4th quarter. NuWave Investment Management LLC now owns 1,281 shares of the healthcare product maker’s stock worth $93,000 after acquiring an additional 1,026 shares during the last quarter. Finally, NewSquare Capital LLC grew its holdings in shares of Abbott Laboratories by 14.2% in the 4th quarter. NewSquare Capital LLC now owns 1,290 shares of the healthcare product maker’s stock worth $93,000 after acquiring an additional 160 shares during the last quarter. 72.71% of the stock is currently owned by hedge funds and other institutional investors.

Get Abbott Laboratories alerts:

In other news, Chairman Miles D. White sold 142,341 shares of Abbott Laboratories stock in a transaction on Wednesday, November 28th. The stock was sold at an average price of $72.35, for a total transaction of $10,298,371.35. Following the transaction, the chairman now owns 3,459,185 shares in the company, valued at $250,272,034.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Jaime Contreras sold 177,457 shares of Abbott Laboratories stock in a transaction on Wednesday, January 30th. The shares were sold at an average price of $70.00, for a total value of $12,421,990.00. Following the transaction, the insider now owns 100,985 shares in the company, valued at approximately $7,068,950. The disclosure for this sale can be found here. Insiders own 0.74% of the company’s stock.

Shares of ABT stock opened at $73.33 on Friday. Abbott Laboratories has a 1-year low of $55.58 and a 1-year high of $74.92. The company has a current ratio of 1.42, a quick ratio of 1.13 and a debt-to-equity ratio of 0.62. The firm has a market cap of $127.76 billion, a PE ratio of 25.26, a price-to-earnings-growth ratio of 1.94 and a beta of 1.14.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Wednesday, January 23rd. The healthcare product maker reported $0.81 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.81. Abbott Laboratories had a return on equity of 16.50% and a net margin of 7.74%. The business had revenue of $7.77 billion for the quarter, compared to the consensus estimate of $7.82 billion. During the same quarter in the previous year, the company posted $0.74 earnings per share. Abbott Laboratories’s revenue for the quarter was up 2.3% compared to the same quarter last year. On average, equities research analysts anticipate that Abbott Laboratories will post 3.2 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, February 15th. Stockholders of record on Tuesday, January 15th will be issued a dividend of $0.32 per share. This is an increase from Abbott Laboratories’s previous quarterly dividend of $0.28. The ex-dividend date is Monday, January 14th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 1.75%. Abbott Laboratories’s payout ratio is currently 44.44%.

A number of equities analysts recently issued reports on the company. Morgan Stanley lifted their target price on Abbott Laboratories from $80.00 to $82.00 and gave the stock an “overweight” rating in a report on Tuesday, December 4th. Goldman Sachs Group upgraded Abbott Laboratories from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $78.00 to $81.00 in a report on Friday, November 30th. Bank of America restated a “buy” rating and issued a $81.00 target price (up from $73.00) on shares of Abbott Laboratories in a report on Thursday. Citigroup cut Abbott Laboratories from a “neutral” rating to a “sell” rating and decreased their target price for the stock from $72.00 to $68.00 in a report on Wednesday, January 2nd. Finally, Argus lifted their target price on Abbott Laboratories to $90.00 and gave the stock an “in-line” rating in a report on Friday, January 25th. They noted that the move was a valuation call. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and sixteen have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $79.48.

TRADEMARK VIOLATION WARNING: This piece was originally reported by Ticker Report and is owned by of Ticker Report. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of US & international trademark and copyright law. The correct version of this piece can be read at https://www.tickerreport.com/banking-finance/4138327/abbott-laboratories-abt-holdings-increased-by-congress-asset-management-co-ma.html.

Abbott Laboratories Company Profile

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraines; and anti-infective clarithromycin, as well as provides influenza vaccine and products that regulate physiological rhythm of the colon.

Featured Story: How Do You Make Money With Penny Stocks?

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Friday, February 8, 2019

Oaktree Capital (OAK) Q4 2018 Earnings Conference Call Transcript

Logo of jester cap with thought bubble with words 'Fool Transcripts' below it

Image source: The Motley Fool.

Oaktree Capital (NYSE:OAK) Q4 2018 Earnings Conference CallFeb. 5, 2019 11:00 a.m. ET

Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:

Operator

Welcome and thank you for joining the Oaktree Capital Group fourth-quarter 2018 conference call. Today's conference call is being recorded. [Operator instructions]Now I would like to introduce Andrea Williams, Oaktree's head of corporate communications and investor relations, who will host today's conference call. Ms.

Williams, you may begin.

Andrea Williams -- Head of Corporate Communications and Investor Relations

Thank you, Lora. And welcome to all of you have joined us for today's call to discuss Oaktree's fourth-quarter and full-year 2018 financial results. Our earnings release issued this morning detailing these results may be accessed through the unitholders' section of our website. Our speakers today are Chief Executive Officer Jay Wintrob, Co-Chairman Howard Marks, and Chief Financial Officer Dan Levin.

We'll be happy to take your questions following the prepared remarks. Before we begin, I want to remind you that comments today include forward-looking statements reflecting our current views with respect to, among other things, our operations and financial performance. Important factors could cause actual results to differ possibly materially from those indicated in these statements. Please refer to our SEC filings for a discussion of these factors.

We undertake no duty to update or revise any forward-looking statements. I'd also like to remind you that nothing on this call constitutes offer to sell or a solicitation of an offer to purchase any interest in any Oaktree fund. Investors and others should note that Oaktree uses the Unitholders' section of its website to announce material information. Accordingly, Oaktree encourages investors and media and others to review the information that it shares on its corporate website at ir.oaktreecapital.com.

During our call today, we'll be making reference to certain non-GAAP financial measures, which exclude our consolidated funds. For a reconciliation of each non-GAAP financial measure to its mostly directly comparable GAAP financial measure, please refer to our earnings press release furnished to the SEC today on Form 8-K. This also may be accessed through the Unitholders section of our website. Today, we announced a quarterly distribution of $0.75 per Class A unit, payable on February 22 to holders of record as of the close of business on February 15.

Finally, we plan to issue our 2018 Form 10-K by the end of February. With that, I'll turn the call over to Jay Wintrob.

Jay Wintrob -- Chief Executive Officer

Thanks, Andrea, and welcome to everyone joining the call this morning. The fourth quarter was very challenging for credit and equity markets around the world. U.S. high-yield bonds suffered their largest monthly decline in three years.

U.S. senior loans had their worst month since August 2011 with the two largest weekly outflows on record for the asset class, and U.S. equities experienced their worst December since the Great Depression. The market declines in the fourth quarter stood in sharp contrast to the optimistic market conditions that prevailed over the first three quarters of the year.

Against this tale of two markets and fast-changing investor sentiment, Oaktree demonstrated solid closed and fund investment performance of negative 1% for the fourth quarter and positive 9% gross for the full year, further validating our disciplined and risk-controlled investment approach. Consistent with our focus on seeking value, we were able to take advantage of the market declines in the fourth quarter by investing $4 billion from our closed-end funds, shifting our posture from a net seller in the first half of 2018 to a net buyer in the back half of the year. Also, we feel good about our strong fundraising of $13 billion of gross capital in 2018. And our current balance of $19 billion of dry powder positions us well for any expansion of investment opportunities across our strategies.

All in all, we're pleased with the progress in our business and the strength of our model. Distributable earnings for full-year 2018 were $613 million, down 15% from 2017 when we had record incentive income from our U.S. private equity strategy. Our solid 2018 investment performance produced strong full-year incentive and investment income totals while generating $297 million of incentives created.

And the distribution we announced today of $0.75 brought total distributions for 2018 to $2.96 per Class A unit. Last year, we made progress in broadening our business, particularly in terms of attracting new clients and raising assets outside the United States. Of the nearly $7.5 billion we raised in closed-end funds, some larger commitments were from clients based in Japan, China, the Middle East, and Latin America, all regions where we've dedicated additional marketing resources over the past few years. Capital from non-U.S.

clients represented approximately half our closed-end and total gross capital raised in 2018. We had a strong fundraising year from intermediary and high net-worth channels, raising approximately $1.4 billion from global high net-worth individuals, family offices, and clients of financial advisory firms such as Morgan Stanley and Merrill Lynch. Together with an additional $2 billion of flows from our sub-advisory and [Inaudible] platforms, we raised about $3.4 billion from these channels across a diverse slate of strategies such as Strategic Credit, Real Estate Debt, Special Situations, and emerging market equities. AUM from intermediary and high net-worth channels comprised about 16% of total Oaktree AUM at year end.

We're particularly encouraged by the growth of several Oaktree strategies last year. First, we continue to make progress in broadening and scaling our real estate platform, which now comprises three strategies. We successfully completed our second real estate debt fund, which closed on over $2 billion. We also laid a terrific foundation for future growth in our newest real estate income fund by generating a very strong first year investment return of 27% before fees.

We're currently leveraging our real estate income team by launching Oaktree REIT. And finally, this year, we'll be raising our eighth real estate opportunities fund. Second, we successfully increased the scale of and diversified our direct lending platform and raising $800 million for our middle-market direct lending fund for institutional clients and over $300 million for private BDC for high net-worth clients. Our private alternative credit strategies now total nearly $8 billion.

Third, we grew our assets for power opportunities significantly by raising our largest fund ever for that strategy, $1.4 billion in a single close. This strategy continues to generate outstanding investment performance, holding the enviable position of Oaktree's highest-performing closed-end strategy since its inception in 1999. This is a great testament to the positive impact of discipline in setting the size of funds. Fourth, our emerging market debt platform made good progress last year, raising almost $900 million in our emerging markets opportunities and emerging markets debt total return strategies.

Fifth, our value-based approach to emerging market equities delivered strong outperformance versus the benchmark in 2018. And we were able to attract over $1.2 billion in gross capital during the year with a solid pipeline for additional flows in the next couple of quarters. And finally, we continued to see strong investment performance from the global credit strategy. Over its nearly two-year life, the global credit strategy has outperformed its benchmark on an annual basis by 1.5% gross.

And in 2018, we raised $650 million for the strategy and are continuing to see a lot of interest from new and existing clients. Looking ahead to this year, we have momentum from the growth in our strategies and distribution organization and from the continuation of fundraising efforts for Special Situations Fund II, Emerging Markets Debt and Equity funds, the Real Estate Income fund, and the Global Credit Fund. And this year, we anticipate launching, in addition to the real estate Opportunities Fund VIII, our Fifth European Principal Fund, our Second European Capital Solutions Direct Lending fund, Mezzanine Fund V, Oaktree REIT and various structured credit vehicles as well as engaging an ongoing fundraising for our evergreen strategies, in particular the Value Opportunities fund and strategic credit. Turning to our open-end strategies, we were not immune to the industry fund outflows that took place throughout last year, including record redemptions in the high-yield bond and senior loan asset classes during the fourth quarter.

Within our open-end strategies, Oaktree experienced about $4 billion in net outflows last year, primarily from our high-yield bond and convertible securities strategies. However, we're encouraged by strong investment track records for our European high-yield bond and senior U.S. loan and U.S. senior loan products and increased investor demand for our emerging markets equity strategy.

Looking back on 2018, I'm very proud of our Oaktree team, a remarkably talented, dedicated, and hardworking professionals. Viewing things from a high level, I think we achieved success on three fronts: first, investing well while adhering to our focus on the privacy risk control; second, raising $13 billion of gross capital through a broad range of Oaktree strategies and products; and third, continuing to expand the investment strategies that have been most important to the growth of our diversified platform in recent years, namely real estate, infrastructure, emerging markets debt and equity and direct lending. Right now, I believe our best opportunities for future growth will come from continuing to scale many of these strategies, successfully deploying an increasing amount of capital across the globe in our flagship-distressed debt strategy and capitalizing on the strong performance track records of our private equity strategies and several of our open-end and evergreen strategies. And with that, let me turn the call over to Howard to discuss our investment performance and the market environment.

Howard Marks -- Co-Chairman

Thanks, Jay, and hello, everyone. What an interesting year 2018 was. The market psychology proved to be incredibly volatile as a broad sell-off took hold of the markets in the first week of October and continued nearly unabated through year end. This was driven by no new real concerns as the withdrawal of central bank liquidity, increase in interest rates, slower global growth, all had been foretold well in advance as had the geopolitical tensions regarding trade.

On October 3rd, everything was fine with the markets. On October 4th, the equity market began one of the biggest declines ever seen over such a short period of time, leading to the worst December since the Great Depression. But as I wrote in on the couch in early 2016 when the markets got off to one of their worst starts in history, in the real world, things tend to fluctuate between pretty good and not so hot. But in the market, things swing between flawless and hopeless, and that's what happened in the fourth quarter.

Against this turbulent backdrop, the composite full-year returns for our closed-end funds and evergreen strategies were largely outstanding and well above the public securities indices. The composite gross return for the distressed debt strategy was 10%, power opportunities, 13%, European principal 11%, real estate opportunities 15%, and U.S. private debt 12%. As an aside, I believe we had a particularly good year relative to our competition in our very important distressed debt strategy with a fourth-quarter gross return of negative 1.5% and a full-year return of 10%.

As a result, Opps X, which already has seen its committed capital invested more than once against the very lackluster background for opportunities in distress over the last two and a half years shows an attractive absolute return and adds further to Oaktree's luster. The emerging markets opportunities debt strategy came in at 8% and special situations private equity at 1% for the year due to its exposure to certain public equities in the tech sector. Among our evergreen strategies, the two largest, Strategic Credit and Value Opportunities, had 2018 full-year gross returns of 4% and 11%, respectively. While our open-end strategies generally performed in line with their benchmarks, some did better, of course, and some did worse.

The conspicuous outperformers were U.S. senior loans, European high-yield, and emerging markets equities. And in a difficult fourth quarter, six of the nine open-end strategies beat their benchmarks. So, where do we stand today? I see the fourth-quarter price action as a dash of cold water that cooled off some unwarranted enthusiasm.

All of a sudden, credit spreads widened and it was hard to raise money or refinance debt. I take these as signs of helpful prudence. That said, those losses now have been recovered to a large degree, so I'd say investors were chastened but back to being optimistic, especially with developments with the Fed and trade with China now perceived as positive. I continue to believe that asset prices are relatively high and as the fourth quarter proved, investor psychology is fragile.

As we begin 2019, the outlook for defaults in corporate credit remains quite benign with strategists projecting high-yield bond and leverage loan defaults about 1% -- 1.5%, well below the long-term averages in the areas of 3%. Thus, the supply of U.S. distressed tradable investment opportunities may continue to be modest. We saw in the fourth quarter the ability of our teams to deploy capital into some high-quality traded credit opportunities in weak times.

As 2019 has started off with a relief rally, the focus of the distressed debt teams active pipeline has reverted to private deals in Europe and Asia, and attractive opportunities in sectors such as telecom, healthcare, and retail. Now is a good time to have dry powder, and we do, given the outstanding amounts of low-quality debt and fallen angel candidates, BB debt that could be downgraded. They are significantly greater than they were prior to past times of expanded opportunity. Now I'd like to turn the call over to Dan to discuss the financials in detail.

Danie Levin -- Chief Financial Officer

Thank you, Howard. Reflecting upon the year as a whole, we are pleased with our financial performance. For the full year, we generated adjusted net income and distributable earnings per Class A unit of $2.53 and $3.61, respectively, and we distributed $2.96 per unit to our Class A unitholders. Management fees declined $24 million or 3% to $790 million.

As I've mentioned on prior calls, the elevated pace of realizations, especially in the first half of the year, has reduced our management fee-generating AUM for our closed-end funds, and the net outflows have had a similar impact on our open-end funds. This decline was partially offset by fees from our B2C acquisitions in late 2017. Turning to expenses, compensation and benefits increased $18 million in 2018, primarily resulting from expenses related to the Highstar infrastructure team, as I've mentioned before. This amount reflects existing expenses of infrastructure business that were previously paid for by a legacy Highstar fund that, as scheduled, stopped paying management fees in the fourth quarter of 2017.

G&A expenses increased by $22 million, primarily a result of increases of $10 million in placement fees and $5 million related to the Highstar infrastructure team. The higher placement fees were driven largely by the $5 billion increase in closed-end capital raised versus 2017, with closed-end funds representing 59% of the year's total capital raised compared to 28% a year ago. As Jay mentioned, we have grown intermediary and high net worth distribution and have offered an increasing number of products through these channels, which represents a nice diversification of our client mix and comes with incremental G&A expenses. As a result of lower closed-end and open-end management fees and increased expenses, fee-related earnings in 2018 declined 22% to $228 million.

Incentive income for the year totaled $496 million, driven by strong realizations in the distressed debt, special situations, and real estate strategies. The largest contributor was distressed debt at $262 million. Investment income was $49 million in 2018. We recognized a $38 million investment income loss in the fourth quarter, primarily driven by mark-to-market declines in public equity positions across various strategies.

Not surprisingly, many of these declines are proving temporary. Moving to DoubleLine, we continue to be impressed with the company's investment and operating performance, especially in light of the market declines in mutual fund outflows witnessed in the fourth quarter. AUM grew 2% in 2018 as the firm continued to diversify from core fixed-income products into an increasing array of equity, real estate, and commodity-related funds. Over the last year, DoubleLine contributed $74 million to Oaktree's distributable earnings, up 4% from 2017.

In terms of capital structure, over the past year, we strengthened our balance sheet to maximize operational flexibility and increase dry powder at the corporate level. We extended the maturity of our $150 million term loan and $500 million revolver, both now maturing in March 2023, and issued two perpetual preferred securities, raising $400 million in net proceeds. As a result, we are well-positioned to take advantage of opportunities to invest in these strategies and potentially, for an inorganic strategic growth. Net incentives created in 2018 were $148 million, bringing our net accrued incentives balance for the year to $812 million or $5.17 per operating group unit.

39% of our net accrued incentives is represented by private equity strategies, 31% by distressed debt, and 24% by real assets. Of our net accrued incentives balance, 29% is in funds that are currently paying incentives. Turning to the outlook for 2019, we reiterate prior comments that we do not expect management fees to grow until the start of investment period of Opps Xb, which we still estimate will be in the second half of 2019. While we're off to a good start in deploying capital on Opps Xb with 19% invested as of year end, given the size of the fund, we are going to be patient in starting the investment period and, thus, the time when the fund will pay management fees on committed capital.

With respect to the first quarter of 2019, at this point, our known fund-related investment income proceeds are $5 million. And we have no known net incentive income, thus far. As we generally do in the first quarter, we expect to recognize incentive income from tax-related incentive distributions paid by funds that generate taxable income in 2018 but aren't yet paying regular incentives. Current indications are that net incentive income from tax-related incentive distributions will be approximately $130 million in the first quarter.

The meaningful increase of tax-related incentive income relative to the first quarter of 2018 is driven by European Principal Fund III and Opps X paying tax distributions for the first time. Before I wrap up, I'd like to address the recent decisions by several of our peers to report distributable earnings as their primary earnings metric. We think this is a positive development for the industry, and it aligns well with how we have always thought about our business. In order to simplify our disclosure and enhance comparability, starting with the first quarter of 2019, we will report distributable earnings as our primary earnings measurement and will no longer report adjusted net income or economic net income.

In conclusion, 2018 was a strong year for fundraising and deployment and a solid one for investment performance against a challenging market backdrop. Looking ahead, we are well-positioned to capitalize if market volatility continues, with $19 billion of dry powder at our funds and $1 billion of cash and equivalents on our balance sheet. With that, we're delighted to take your questions. So Lora, please open up the lines. 

Questions and Answers:

Operator

[Operator instructions] And our first question today comes from Jerry O'Hara of Jefferies.

Jerry O'Hara -- Jefferies -- Analyst

Great. Thanks for taking the question. You touched on a little bit there in prepared remarks about how the marks, I guess, were largely temporary on some of the public positions. But could you perhaps talk a little bit about sort of the puts and takes between 4Q and what sounds like a little bit of bounce back here year to date with respect to exposures or just kind of general market rebound and how that's impacted portfolios, thus far? I know it's still early, but any sense would be helpful.

Thank you.

Danie Levin -- Chief Financial Officer

Yes. So, Jerry, to address the publicly traded securities, as we think about them kind of Level 1 and Level 2 securities in our portfolio, we've seen a recovery so far this quarter of a little bit over 50% of the kind of writedowns that we saw in the fourth quarter. So, we're off to a good start in terms of the portfolio and the performance in the first quarter. Harder to give you much insight or color on the Level 3 assets, but clearly, market movements this quarter should be helpful there as well because part of the valuation methodology is based on comparable companies.

Howard Marks -- Co-Chairman

Dan, I would you just add that in the marketable securities categories, where we have benchmarks, we beat the benchmarks in most of them in the fourth quarter. Meaning to say we went down less, and yet our participation in the recovery in the month of January, which is a very strong month, was -- we were right in there with the indices. So, I would say that those four months taken together demonstrated the kind of performance pattern that we and our clients look for.

Jerry O'Hara -- Jefferies -- Analyst

That's helpful color. Thank you.

Operator

And the next question will come from Mike Carrier of Bank of America Merrill Lynch.

Mike Needham -- Bank of America Merrill Lynch -- Analyst

Hey, good morning, everyone. This is Mike Needham in for Mike Carrier. Howard, I was hoping you might expand on the comments. You may have had a larger addressable market for your distressed business.

There does seem to be a lot more debt out there, both high yield and low-rated investment grade. Thinking there could be some offsets, things like companies paying lower tax rates and covenants that are harder to trip, just wondering if you can kind of drill down on that assessment and whether in the fourth quarter, you kind of start to see more debt in the public markets at least that was trading at distressed levels. Thanks.

Howard Marks -- Co-Chairman

Yes. Well, Mike, you -- as you mentioned, there are considerable crosscurrents. On the one hand, the issuance of a low-grade debt has been very strong plus the issuance of BBBs, which has the potential to become low-rated. And the -- it may or may not be synonymous, but the standards for credit issuance has been very loose.

I've put out a memo on September 26 entitled The Seven Worst Words in the World, too much money chasing too few deals. The consequence of that condition is always a weakening in the strength of deals, in addition to an increase in the pricing. So, more issuance, lower quality, and obviously, some fragility in investor attitudes. Some things did get cheap in the fourth quarter, and we were able to put $4 billion to work, which I think is a good plus.

Not merely the existence of the opportunities, but the fact that despite the crumbling -- the seemingly crumbling environment around us, our people were able to cut it out and put money to work. And that's what we should do, but it's always nice to see it happen. On the other hand, as you indicate, part of the weakening of deal structures over the last several years has been the disappearance of covenants. And when there are no covenants, it means everything else being equal that any distress that does arise, defaults, I should say, that does arise, tends to happen later.

It can happen for technical reasons, breach of covenant, and it can only happen for money reasons. So all things being equal, the defaults will come later than they otherwise would have, but they'll probably be worse because by the time company's default having been able to go on for -- and do business for a long time in breach of covenants, they would tend to dissipate more of their assets. So the rating agencies, for example, have estimated that recoveries will be considerably less from this round of financing than in -- at the -- than the historic levels, so many crosscurrents. I think that I would sum up by saying that the stage has been set through, what we call around here, the unwise extension of credit and in particular, the heavy reliance on adjusted EBITDA for an elevated -- for our fourth occasion of elevated opportunities.

We had great opportunities in the funds that were formed in 1991 '01, '02, '06, '07, great opportunities. And we think that the pieces are in place for the fourth such opportunity, but we need an igniter, and that will probably require a recession because, especially given the absence of covenants, you're unlikely to get much of a pickup in defaults and thus, in opportunities for us until you get a recession.

Jay Wintrob -- Chief Executive Officer

Howard, if I could just add a couple of comments specific to Oaktree that I think the fourth quarter reflected. I think that for several years now, we've been methodically and intentionally growing our global platform for distressed debt. And several of the transactions in the fourth quarter included investments in Asia, China, India, for example, as well we still have a very large presence in EMEA. I think for the full year, about 40% of the deployment in our distressed debt strategy was outside the United States, and we continue to have a bigger group of investment professionals located around the globe than we do inside the United States.

So I think that, in addition to the big macro, I think we are positioned globally better than we've ever been.

Howard Marks -- Co-Chairman

I can't let Jay have the last word. And I just want to add, as I said in my prepared remarks, I'm enormously proud of the distressed debt group's behavior over the last three years. They activated Fund X, which was $3.8 billion, I think, in the middle of '15. They got it more than 100% invested despite the [Inaudible] of distressed opportunities, despite the rosy environment, and it's showing very good returns to date at a period -- in a period when most people in distressed debt were, I would say, not able to accomplish anything.

So we did a lot on the investing side and lot on the performance side. Very proud.

Mike Needham -- Bank of America Merrill Lynch -- Analyst

OK. Thank you both.

Operator

The next question will come from Michael Cyprys of Morgan Stanley.

Michael Cyprys -- Morgan Stanley -- Analyst

Hey. Good morning. Thanks for taking the question. Just wanted to ask about the Opps Xb 19% invested here, seems like that -- the pace is picking up.

I guess, if you roll the clock forward from here at this current pace could be, call it, 40% invested by the time you get to the middle of 2019. So, just curious at what sort of level there are you looking to before you start activating fees, maybe how that differs versus what you've done in the past in terms of practice. And then just thoughts around raising another distressed fund, how you're thinking about sizing that, and what the time frame might be, if at the current pace, this fund could be meaningfully deployed by the end of '19.

Danie Levin -- Chief Financial Officer

So, let me take the first part of that. So, in terms of how we're thinking about activating the investment period and, therefore, fees on committed capital, this is a larger fund that we sized up because of some of the things that Howard already mentioned, both in the prepared remarks and some of the responses. And so what we do is we really look at two things. We look at how much has been deployed, which you pointed to, 19%, and that should grow as we get into this year.

And we also look at the opportunities set ahead and how do we think about the pace of deployment, and so I think we will be patient in terms of turning on the investment period, given the greater size of this fund relative to our last fund. So as Howard mentioned, our last fund was $3.6 billion. This is $8.9 billion, and so we may be willing to deploy more of it than we did at the last fund before we start the investment period. So there's no magic number.

It's judge -- we use our best judgment of what we think is in the best interest of our clients, and it will be based on our impressions of how much we've deployed but as importantly, what do we think the prospects for future deployment are.

Howard Marks -- Co-Chairman

And I'd like to add that you asked something about how this squares with best practice. We don't have a lot of experience in this. The idea of delaying the onset of the investment period for fee purposes is a pretty new thing. It happened for the first time sometime within our last few funds.

And as you know, the purpose is to avoid having heavy fees on a fund in the early years when it is only fractionally invested, which fees on the whole thing returns on just a little bit, creates a bad dynamic in the beginning that we decided to spare our clients. So, as Dan says, we're going to do it. You said, if you extrapolate the pace last year, that takes us to 40% by mid-'19. We can't really comment on whether 40% is enough or whether that's a fair extrapolation.

Then you also talked about the outlook for being substantially invested by the end of '19. And if you take those two comments together, what it says is second half of '19, which is what we have always said lately, and I think that's the wise thing to say. Just one reminder, if anybody is listening on the call and has the impression that we're not charging fees in Xb, that's wrong. We're charging fees based on invested capital.

The only thing under discussion is when we switch to charging fees on committed capital for a three-year period.

Jay Wintrob -- Chief Executive Officer

And on that period, I just want there to be no uncertainty. We expect that to be in the back half of this year.

Howard Marks -- Co-Chairman

Jay, you can have the last word on that.

Jay Wintrob -- Chief Executive Officer

No, you got it.

Danie Levin -- Chief Financial Officer

And then, Mike, I think you did ask about the next fund.

Howard Marks -- Co-Chairman

Oh, yes. Good point.

Danie Levin -- Chief Financial Officer

So, it's a little -- it's hard to say exactly when the next one will come. We're obviously making some good progress. We continue to make good progress. You could start -- we would certainly start thinking about that in 2020.

Howard Marks -- Co-Chairman

And I'll throw in that in the fourth quarter in December, when things were cascading down, I was starting to salivate. I mean, we were seeing debt prices plummet, spreads widen out very substantially by a couple of hundred basis points, total inability to issue a high-yield bond in December. For the first time in many years, we had a month without any issuance. So at that moment, we were optimistic both as to the timing and the size of Opps XI and, of course, with the recovery.

We're a counter-indicator. So with the recovery, now we're less optimistic but these things will change a lot between now and then.

Michael Cyprys -- Morgan Stanley -- Analyst

Great. Thank you very much.

Operator

And next, we have a question from Brian Bedell of Deutsche Bank.

Melinda Roy -- Deutsche Bank -- Analyst

Hi. This is Melinda Roy, on for Brian Bedell. Maybe just one on FRE. How should we think about FRE growth and margins in 2019 and into 2020, given your management fee guidance on Opps Xb and any other fundraising efforts?

Danie Levin -- Chief Financial Officer

Thanks, Melinda. So, the biggest driver of FRE margin is going to be the trajectory of our management fees. And so in the first part of the year, we don't expect management fees to grow. And as I think about expenses for 2019, I expect G&A to be roughly similar to what we saw this year, noting that placement fees can vary quarter to quarter as well as year to year.

In terms of comp and benefits, I do expect there to be kind of mid- to high single-digit percent growth in comp and benefits next year, reflecting some of the investments we've made, particularly in building out our Asia investment capabilities as well as distribution capabilities. So add that all up, you could see a little bit of FRE pressure in the first part of the year. When Opps Xb starts its investment period, we would expect management fees to step up and our FRE margins to step up into the 30s as a result. As we look into 2020, I think we could see continued FRE margins in the kind of low to mid-30s, and it will partially depend on the timing -- the pace of deployment and the timing of turning on some of the other funds that we're raising, such as some of the ones that Jay mentioned, including Real Estate Fund VIII, European Principal Fund V, among others.

Melinda Roy -- Deutsche Bank -- Analyst

Thank you.

Operator

And the next question comes from Alex Blostein of Goldman Sachs.

Alex Blostein -- Goldman Sachs -- Analyst

Great. Hey, good morning, everybody. Howard, Iwanted to start with a question around fundraising and sort of the LP's response to the events in December and the volatility and, obviously, the subsequent improvement we saw in January. So is that in any way accelerating or, in the other hand, delaying some of the fundraising initiatives you have in place? And really, just, again, hoping to get a better check on the pulse of how LPs have responded to this brief period.

Howard Marks -- Co-Chairman

I think, it's too soon to say, Alex. We're only one month into the new year. We're only a few days past the end of that highly volatile recovery month. I think that, if I'm not mistaken, the resurrection of what I would call prudence in the fourth quarter, whenever prudence is rewarded, Oaktree does better in client reception because they say, "Oh, yes.

Now I remember why we like Oaktree because they don't go down as much and because they swing into action in tough times." So -- and I think that that's all going on now. And we had nine years in which there were very few reminders of the need for prudence. So, I think that our -- I think our receptivity is very good. And by the way, people give me credit for being cautionary in my last memo and they let me off the hook for having been cautionary over several memos well before that.

Alex Blostein -- Goldman Sachs -- Analyst

Great. Fair enough. And then, Dan, can I just sneak one more? In your comments around the balance sheet and the fact that you guys, obviously, have a lot of dry powder in the funds but as well as on the balance sheet, and you did highlight inorganic opportunities. Could you guys expand on that a bit more and what you could find interesting right now?

Danie Levin -- Chief Financial Officer

So currently, it's consistent with our prior comments, not unlike our general view of the investment environment. There's lots of capital. Prices are high. There are minority stake investors that are active in the market.

So as a general comment, I'd say, we're pretty cautious on M&A in this environment but we certainly understand and appreciate the prudence of having capital available when times change, when sentiment in psychology evolve and when the opportunity set gets larger. So to sum it up, I think we're going to be quite cautious in the current environment, but we think it's prudent to have available capital for a different environment.

Alex Blostein -- Goldman Sachs -- Analyst

Yes. Fair enough. Thank you, guys.

Operator

And our next question comes from Chris Harris of Wells Fargo.

Chris Harris -- Wells Fargo Securities -- Analyst

Thanks, guys. So your investment performance in the fourth quarter better than your expectations, better than benchmarks, better than your peers. Yes, and it might be a little hard to generalize, but what do you attribute that outperformance to specifically in the quarter? Is it just that perhaps you're a little bit higher up on the quality spectrum and that kind of drill? Or was it something more broad than that?

Howard Marks -- Co-Chairman

We'll, I'd love to say we're smarter. But most of it is that our approach to investing emphasizes good participation in benchmark returns when they're good and protection against declines when there are declines. And so we really get to show our stuff in tough quarters, and I think we did, as a result. I think that's most of it.

There's nothing specific. I mean, we -- for many years, we've been fully invested but cautiously and the fourth quarter was a period when it paid off extremely well, and there hadn't been many such periods but I'm proud of having remained fully invested. That's really the key. Our caution has permitted us the confidence to remain fully invested over this period, and that means that we have participated in most or all or sometimes even more than the benchmark returns.

And then, when the stuff hits the fan to outperform on the way down. That's really our ideal.

Operator

OK. Our next question comes from Patrick Davitt of Autonomous Research.

Patrick Davitt -- Autonomous Research

Hey. Good morning. Thank you. Howard, you mentioned the fourth big opportunity is emerging and the potential salivation in the fourth quarter.

So with that in mind and the view that there's probably a lot more paper this time around out there than in '07, '08, and how quickly you raised VIIb when that opportunity became clear, have you guys done some work around how much bigger the addressable market when that opportunity comes and what percentage of that you think becomes a good Oaktree investment?

Howard Marks -- Co-Chairman

It -- I mean, I would say we don't generally do that kind of speculative thinking. We just -- I mean, look, these markets have doubled in sized in the last 10 years. That's the most important thing. The quality is lower, which implies that one of these days, there's going to be a high default rate once we cleared the requirement for a recession.

And given the fact that recoveries are likely to be low, that means purchase prices may cascade downward. So, it's all good for a good-sized Opps XI. But still, we need a -- we need an entry point to make that decision as it seemed to be foreshadowed in the fourth quarter but now seems to have disappeared. So, we don't take a scientific approach to this.

We use the judgment from having been in the distressed business over 30 years, and I'm sure we'll continue to use that judgment.

Jay Wintrob -- Chief Executive Officer

Howard, if I can just add, and then you'll comment.

Howard Marks -- Co-Chairman

Yes, Jay.

Jay Wintrob -- Chief Executive Officer

To put in a word for -- and I completely concur with Howard's comments about the accomplishments of our distressed debt team and the potential, but I also want to put in a strong word for so many other Oaktree strategies that, during these past years, including '18, have continued to expand. And so you get into the numbers, we've seen increased deployment in -- both in our European Principal group and our European Private Debt group. We've seen meaningful increased deployment across all three strategies for real estate, the power opportunity strategy, and the infrastructure strategy, greater deployment this year than in prior, and both emerging markets debt and equity. And that's not even to speak about other aspects of our direct lending platform like the BDCs and Strategic Credit.

So, I just wanted to make sure that we didn't paint an imbalanced picture about the growth and expansion across Oaktree and what's really been driving it, leading up to this very interesting period that we're heading into for distressed debt.

Howard Marks -- Co-Chairman

Well, a good point, Jay. And everybody tends to think of us as being dominated by the opportunities funds. And they are important to us but as Jay says, they're not everything. The opportunities fund, I noted in Jay's remarks, the opportunities funds are not even the biggest factor anymore in our accrued incentives.

They are 31, I think, versus 39 for the private equity. So it's -- and when I look at our performance summary for the year, which Andrea Williams was good enough to furnish me to get me going on my annual review, it's really exciting to look down the list and see so many of the closed-end deal [Inaudible] exciting? OK. And to see so many of the closed-end strategies with double-digit returns for 2018, which was not a great year by most accounts.

Patrick Davitt -- Autonomous Research

Thank you.

Operator

This concludes our question-and-answer session. I would like to turn the conference back over to Andrea Williams for any closing remarks.

Andrea Williams -- Head of Corporate Communications and Investor Relations

Thank you, everyone, for joining us for the fourth-quarter 2018 earnings conference call. The replay for this conference call will be available approximately one hour after this broadcast on Oaktree's website in the Unitholders' section. You may also access the replay by dialing (877) 344-7529 in the U.S. or 1 (412) 317-0088 outside of the U.S.

The replay access code is 10127530. Thank you very much.

Operator

[Operator signoff]

Duration: 50 minutes

Call Participants:

Andrea Williams -- Head of Corporate Communications and Investor Relations

Jay Wintrob -- Chief Executive Officer

Howard Marks -- Co-Chairman

Danie Levin -- Chief Financial Officer

Jerry O'Hara -- Jefferies -- Analyst

Mike Needham -- Bank of America Merrill Lynch -- Analyst

Michael Cyprys -- Morgan Stanley -- Analyst

Melinda Roy -- Deutsche Bank -- Analyst

Alex Blostein -- Goldman Sachs -- Analyst

Chris Harris -- Wells Fargo Securities -- Analyst

Patrick Davitt -- Autonomous Research -- Analyst

More OAK analysis

This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.

10 stocks we like better than Oaktree CapitalWhen investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Oaktree Capital wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of January 31, 2019